STAT+: Startup promising to scale custom CRISPR therapies abruptly scraps plans — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Aurora Therapeutics scrapped its lead personalized gene-editing program and slashed staff just seven months after the company launched, according to STAT
- A company spokesperson declined to disclose how many employees were laid off or whether any of the startup's three-person leadership team would remain
- Aurora's chief scientific officer departed the company earlier this year
- Beam Therapeutics, a larger and more established competitor, announced it was already advancing its own set of custom gene editors for the exact same disease just one month after Aurora launched
- Aurora's lead program appeared to have been undercut by Beam's faster progress on the identical indication, erasing the startup's first-mover position before it could gain traction
Why it matters: Personalized CRISPR therapy is a capital-intensive race where being first to a disease target is the entire value proposition — Aurora launched, Beam announced the same indication a month later, and seven months after launch Aurora was gutted. The episode shows how a well-funded incumbent entering the same indication within weeks can wipe out a startup's runway before clinical proof-of-concept even arrives.
Ask SkimNews
